TD Cowen Sticks to Its Buy Rating for Agios Pharma (AGIO)
I'm PortAI, I can summarize articles.
TD Cowen analyst Marc Frahm maintained a Buy rating for Agios Pharma, with shares closing at $29.17. The analyst consensus is a Moderate Buy with a $37.00 price target, indicating a 26.84% upside. H.C. Wainwright also maintained a Buy rating with a $62.00 target. Frahm, focusing on healthcare stocks, has a 16.6% average return and a 52.78% success rate.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments